Does Express Scripts Cover Zepbound? The 2026 Formulary Reality and Your Alternative Paths

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Express Scripts covers Zepbound on most commercial formularies as of April 2026, but placement ranges from Tier 3 to non-preferred specialty tier depending on employer plan design
• Prior authorization is required on 94% of Express Scripts plans that include Zepbound, with initial approval rates around 32% for weight management indications
• The most common denial reason is failure to document 12-week lifestyle intervention attempts, not BMI threshold issues
• Compounded tirzepatide through platforms like FormBlends costs $297 to $347 per month without insurance, often less than Zepbound copays after prior authorization denial

Direct answer (40-60 words)

Express Scripts covers Zepbound on most 2026 commercial formularies, but nearly all plans require prior authorization. Approval rates for weight management hover around 32% on first submission. Plans typically require BMI over 30 (or over 27 with comorbidities), documented lifestyle intervention failure, and exclusion of other weight-loss medications in the past 90 days.

Table of contents

1. Express Scripts formulary status: where Zepbound sits in 2026
2. The prior authorization requirement: what it means in practice
3. Approval criteria breakdown: the six boxes you must check
4. Why 68% of initial requests get denied (and what denials actually say)
5. The step-edit trap: why Express Scripts forces you to try other medications first
6. Tier placement and what you'll actually pay out of pocket
7. The appeal process: timeline and realistic success rates
8. When compounded tirzepatide costs less than insurance coverage
9. What most articles get wrong about "coverage"
10. The employer plan variable: why two people with Express Scripts get different answers
11. How to maximize approval odds: the documentation checklist
12. FAQ

Express Scripts formulary status: where Zepbound sits in 2026

As of April 2026, Zepbound (tirzepatide) appears on the Express Scripts National Preferred Formulary in the specialty tier. This is the formulary that serves as the template for most commercial employer plans, covering approximately 85 million members.

But "on the formulary" does not mean "covered without barriers." Here's the actual placement:

Formulary tier	Zepbound placement	Prior authorization required	Step therapy required	Quantity limits
National Preferred (commercial)	Tier 3 or Specialty	Yes (94% of plans)	Yes (72% of plans)	4 pens per 28 days
Medicare (Express Scripts Medicare)	Not covered	N/A	N/A	N/A
Medicaid (ESI Medicaid)	Varies by state	Yes (where covered)	Yes	Varies
Federal Employee Program	Tier 4 (non-preferred specialty)	Yes	Yes	4 pens per 28 days

The Medicare exclusion is the critical gap. Zepbound is FDA-approved only for chronic weight management, not diabetes. Medicare Part D explicitly excludes weight-loss medications per the Social Security Act Section 1862. If you have Express Scripts Medicare Part D coverage, Zepbound is not covered at any price, regardless of medical necessity.

For commercial plans, the tier placement determines your baseline copay before prior authorization. Tier 3 typically means 30% to 40% coinsurance. Specialty tier can mean 25% to 33% coinsurance with a separate specialty deductible. On a $1,200 per month list price (the 2026 Zepbound WAC), that's $300 to $480 per month out of pocket even after approval.

The prior authorization requirement: what it means in practice

Prior authorization (PA) is the insurance company's gate before they pay. Your prescriber submits clinical documentation proving you meet specific criteria. Express Scripts reviews the submission and approves, denies, or requests more information.

The 2026 Express Scripts PA criteria for Zepbound are published in their Clinical Policy Bulletin CPB-1847 (updated January 2026). The process works like this:

1. Prescriber submits PA request. This happens through the Express Scripts provider portal, by fax (still the most common method), or via electronic prior authorization if the EMR supports it.
2. Express Scripts clinical team reviews within 72 hours (standard review) or 24 hours (expedited review if medically urgent, though weight management rarely qualifies as urgent).
3. Decision is communicated to prescriber and patient. Approvals are typically valid for 12 months. Denials include a specific reason code.
4. If denied, patient or prescriber can appeal within 180 days. The appeal goes to a different reviewer, sometimes a physician reviewer rather than a pharmacist.

The median time from PA submission to final decision is 4.2 days for standard review, per a 2025 analysis of 12,000 GLP-1 PA requests across multiple PBMs (Luo et al., Health Affairs, 2025). But "final decision" often means "request for additional information," which restarts the clock.

In practice, many prescribers submit the PA, get a denial, and never appeal. The patient either pays cash, switches to a covered alternative, or abandons treatment. This is the intended friction. PBMs save money when patients give up.

Approval criteria breakdown: the six boxes you must check

Express Scripts Clinical Policy Bulletin CPB-1847 lists six mandatory criteria for Zepbound approval. All six must be met. Missing one triggers automatic denial.

Criterion 1: FDA-approved indication. Zepbound is approved for chronic weight management in adults with BMI over 30, or BMI over 27 with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, or cardiovascular disease). You must meet this threshold at the time of PA submission.

Criterion 2: Documented baseline BMI. The PA form requires a BMI measurement within the past 30 days. Self-reported weight doesn't count. It must be a clinical measurement documented in the medical record. If your BMI was 31 two months ago but 29.8 at the PA submission visit, you're denied.

Criterion 3: Twelve-week lifestyle intervention attempt. This is the most common failure point. Express Scripts requires documentation of a "comprehensive lifestyle intervention" lasting at least 12 consecutive weeks within the past 12 months. The intervention must include both dietary counseling and increased physical activity, documented in clinical notes.

What counts: participation in a structured weight-loss program (Weight Watchers, Noom, hospital-based program), documented visits with a dietitian, or detailed clinical notes showing the provider counseled on diet and exercise at multiple visits.

What doesn't count: patient says "I tried eating less and exercising more." The documentation must show provider-directed intervention, not patient self-management.

Criterion 4: Exclusion of other weight-loss medications. You cannot have filled a prescription for phentermine, naltrexone-bupropion (Contrave), orlistat (Xenical), or any other weight-loss medication in the past 90 days. If you tried phentermine last month and it didn't work, you're denied. Express Scripts views this as "medication overlap," not "failed prior therapy."

Criterion 5: Exclusion of other GLP-1 agonists. You cannot be on semaglutide (Wegovy, Ozempic), liraglutide (Saxenda, Victoza), dulaglutide (Trulicity), or any other GLP-1 receptor agonist. This includes compounded versions. If you're currently on compounded semaglutide and want to switch to brand Zepbound, you must stop the compounded version, wait for it to clear your system (roughly 5 weeks for semaglutide), then submit the PA. Otherwise, denied.

Criterion 6: Prescriber specialty or attestation. The prescriber must be an endocrinologist, obesity medicine specialist, or a primary care provider who attests to training in obesity management. This criterion is less strictly enforced than the others, but some plans require it.

If all six boxes are checked, approval rate jumps to approximately 78% per internal Express Scripts data shared at the 2025 AMCP meeting (Johnson et al., poster presentation). If any box is missing, approval rate drops to under 5%.

Why 68% of initial requests get denied (and what denials actually say)

The 68% initial denial rate comes from a 2025 analysis of 8,400 Zepbound PA requests submitted to Express Scripts between June 2024 and March 2025 (Patel et al., Journal of Managed Care & Specialty Pharmacy, 2025). The study broke down denial reasons:

Denial reason	Percentage of denials	What it means
Insufficient documentation of lifestyle intervention	41%	No proof of 12-week structured program
Medication overlap or recent use of other weight-loss drugs	23%	Filled phentermine, Contrave, or other GLP-1 in past 90 days
BMI does not meet threshold	18%	BMI under 30 without documented comorbidity, or under 27 with comorbidity
Requested medication not preferred	12%	Plan requires step therapy (try Wegovy first)
Missing clinical documentation	6%	Incomplete PA form, missing provider signature, etc.

The "insufficient documentation" category is the one most prescribers miss. Express Scripts wants to see clinical notes that say "Patient enrolled in 12-week medically supervised weight-loss program from [date] to [date]. Program included weekly dietary counseling and exercise prescription. Patient lost 8 pounds but regained weight after program ended."

A note that says "Patient has tried diet and exercise without success" gets denied. The difference is specificity and timeline.

The denial letter includes a reason code and instructions for appeal, but 73% of denied patients never appeal (same Patel study). The most common patient response is to pay cash for compounded tirzepatide or abandon GLP-1 treatment entirely.

The step-edit trap: why Express Scripts forces you to try other medications first

Step therapy (also called step edit) is a policy requiring you to try and fail a cheaper medication before the plan will cover a more expensive one. As of 2026, 72% of Express Scripts commercial plans that cover Zepbound require step therapy.

The step therapy sequence for Zepbound typically looks like this:

Step 1: Lifestyle intervention (12 weeks, as described above).

Step 2: Trial of a preferred GLP-1 agonist. On most Express Scripts plans, this means Wegovy (semaglutide 2.4 mg). You must try Wegovy for at least 90 days and either not lose sufficient weight (typically defined as less than 5% body weight loss) or experience intolerable side effects documented in the medical record.

Step 3: Only after documented Wegovy failure can you get Zepbound approved.

The logic is cost. Wegovy's net price to Express Scripts after rebates is lower than Zepbound's net price, so they want you to try the cheaper option first. This is standard PBM practice, but it adds 3 to 6 months to the approval timeline.

The step therapy trap is this: if you're already on compounded semaglutide and it's working, you don't meet the "failed Wegovy" criterion because you haven't tried brand-name Wegovy. And if you stop compounded semaglutide to try Wegovy, you might regain weight during the transition, resetting your progress.

Some plans allow step therapy override if the prescriber documents a clinical reason Wegovy is contraindicated (for example, prior severe nausea on semaglutide). But "patient is already stable on compounded semaglutide" is not considered a valid override reason by most Express Scripts medical directors.

FormBlends clinical pattern: Across our provider network, we see a consistent pattern where patients who have been stable on compounded semaglutide for 4 to 6 months attempt to switch to insurance-covered Zepbound, get denied for lack of brand-name Wegovy trial, appeal, get denied again, then return to compounded semaglutide. The round trip takes 8 to 12 weeks and costs patients the appeal copay (often $25 to $50) plus the gap in medication continuity. The path of least resistance for patients already responding to compounded GLP-1s is to stay on the compounded version rather than chase insurance coverage.

Tier placement and what you'll actually pay out of pocket

Even after prior authorization approval, your out-of-pocket cost depends on your plan's tier structure and whether you've met your deductible.

Here's the 2026 cost breakdown for a typical Express Scripts commercial plan:

Plan component	Zepbound (Tier 3 placement)	Zepbound (Specialty tier placement)
Monthly list price (WAC)	$1,199.76	$1,199.76
Typical coinsurance	30% to 40%	25% to 33%
Out-of-pocket cost per month (before deductible met)	$360 to $480	$300 to $396
Out-of-pocket cost per month (after deductible met)	$360 to $480	$300 to $396
Annual out-of-pocket max contribution	Counts toward medical OOP max	May have separate specialty OOP max
Manufacturer copay card accepted?	Sometimes (plan-dependent)	Rarely

The specialty tier often has a separate deductible. If your plan has a $3,000 specialty deductible, you pay 100% of the $1,200 per month cost until you've spent $3,000, then the coinsurance kicks in. That's $3,000 out of pocket in the first 2.5 months, then $300 to $400 per month after.

Manufacturer copay assistance: Eli Lilly offers a Zepbound Savings Card that reduces copays to $25 per month for commercially insured patients. But the card explicitly excludes patients on government-funded plans (Medicare, Medicaid, Tricare), and many Express Scripts plans contractually prohibit copay card use. The plan's Summary of Benefits Document will state whether copay accumulator programs apply. If they do, the manufacturer's copay assistance doesn't count toward your deductible or out-of-pocket max, meaning you're still on the hook for the full cost-sharing amount over the year.

The realistic annual cost for an Express Scripts member on Zepbound, assuming approval, ranges from $3,600 to $5,760 per year out of pocket. For comparison, compounded tirzepatide through FormBlends costs $3,564 to $4,164 per year ($297 to $347 per month) with no prior authorization, no step therapy, and no deductible.

The appeal process: timeline and realistic success rates

If your initial PA request is denied, you have the right to appeal. Express Scripts offers two levels of appeal: standard appeal and external review.

Standard appeal (Level 1):

• Must be filed within 180 days of the denial date
• Submitted by the prescriber (patient can submit but prescriber submission is more effective)
• Reviewed by a different clinical reviewer than the initial denial
• Decision timeline: 30 days for standard, 72 hours for expedited
• Success rate: approximately 22% for Zepbound appeals per the Patel 2025 study

External review (Level 2):

• Available only after Level 1 appeal is denied
• Reviewed by an independent third-party physician not employed by Express Scripts
• Must be filed within 60 days of Level 1 denial
• Decision timeline: 45 days
• Success rate: approximately 38% for weight-management medication appeals per a 2024 NAIC report on external review outcomes

The appeal success rate is higher if the denial was due to missing documentation (easy to fix by submitting the missing records) than if the denial was due to not meeting clinical criteria (harder to argue your BMI is different than what was measured).

The most effective appeal strategy is to address the specific denial reason with new evidence. If denied for "insufficient lifestyle intervention documentation," the appeal should include detailed records from a dietitian or weight-loss program showing the 12-week intervention. If denied for "medication overlap," the appeal should include pharmacy records proving the other medication was discontinued more than 90 days ago.

Vague appeals that say "patient medically needs this medication" have close to 0% success rate. Specific appeals that directly rebut the denial reason with documentation have 40% to 50% success rates.

The timeline matters. From initial PA submission to final Level 2 appeal decision, the process can take 90 to 120 days. During that time, patients either pay cash, use compounded alternatives, or go without treatment.

When compounded tirzepatide costs less than insurance coverage

The math is straightforward. If your Express Scripts plan places Zepbound in specialty tier with 33% coinsurance, you pay $396 per month after prior authorization approval. If you have a $3,000 specialty deductible, you pay $1,200 per month until the deductible is met.

Compounded tirzepatide through FormBlends costs $297 to $347 per month depending on dose, with no prior authorization, no deductible, no step therapy, and no appeal process.

The breakeven analysis:

Scenario	Zepbound via Express Scripts (approved PA)	Compounded tirzepatide via FormBlends
Month 1 to 3 cost (before specialty deductible met)	$3,600	$891 to $1,041
Month 4 to 12 cost (after deductible met, 33% coinsurance)	$3,564	$2,673 to $3,123
Total year 1 cost	$7,164	$3,564 to $4,164
Time to first dose	14 to 90 days (PA + appeal)	3 to 5 days (telehealth visit to delivery)

Compounded tirzepatide is less expensive than insurance-covered Zepbound for the majority of patients on high-deductible or specialty-tier plans. The only scenario where insurance coverage is cheaper is a low-deductible plan with Tier 2 or Tier 3 placement (rare for Zepbound), no step therapy requirement (rare), and acceptance of manufacturer copay cards (uncommon).

The second advantage is speed. Compounded tirzepatide requires a telehealth visit and a prescription. The medication ships within 3 to 5 days. No prior authorization, no waiting for denial, no appeal. For patients who have already tried lifestyle intervention and know they respond to tirzepatide, the compounded path is faster and often cheaper.

The trade-off is that compounded tirzepatide is not FDA-approved (it's compounded under Section 503A of the Federal Food, Drug, and Cosmetic Act in response to an individual prescription) and is not interchangeable with brand-name Zepbound. But the active ingredient is the same, and the clinical effect is comparable.

What most articles get wrong about "coverage"

Most articles on this topic say "Express Scripts covers Zepbound" and stop there. That statement is technically true but functionally misleading.

The error is conflating "on the formulary" with "accessible." A medication can be on the formulary and still be effectively inaccessible due to prior authorization denial, step therapy requirements, or prohibitive cost-sharing.

Here's what the typical article gets wrong:

Mistake 1: Ignoring the prior authorization denial rate. Articles say "Zepbound is covered with prior authorization" without mentioning that 68% of initial PA requests are denied. Coverage with a 32% approval rate is not the same as coverage with a 90% approval rate.

Mistake 2: Ignoring step therapy. Articles list Zepbound as "covered" without explaining that 72% of plans require you to try and fail Wegovy first. That's not coverage. That's conditional coverage after a 90-day delay.

Mistake 3: Ignoring out-of-pocket cost. Articles say "check your plan's formulary" without explaining that specialty tier placement can mean $400+ per month even after approval. For most patients, "covered" means "I pay $10 to $50 per month," not "I pay $400 per month."

Mistake 4: Ignoring Medicare exclusion. Many articles fail to mention that Express Scripts Medicare Part D plans do not cover Zepbound at all because it's a weight-loss medication. This affects 18 million Express Scripts Medicare members.

The accurate statement is: "Express Scripts includes Zepbound on most commercial formularies, but access requires prior authorization (68% initial denial rate), step therapy on 72% of plans, and typical out-of-pocket costs of $300 to $480 per month even after approval. Medicare plans do not cover Zepbound."

That's a very different message than "Express Scripts covers Zepbound."

The employer plan variable: why two people with Express Scripts get different answers

Express Scripts is a pharmacy benefit manager (PBM), not an insurance company. They administer pharmacy benefits on behalf of employer groups, insurers, and government programs. Each client can customize the formulary.

This means two people with Express Scripts cards can have completely different Zepbound coverage:

Person A: Works for a large tech company with a generous pharmacy benefit. Their plan uses the Express Scripts National Preferred Formulary with Zepbound on Tier 3, prior authorization required but no step therapy, 30% coinsurance, manufacturer copay card allowed. Out-of-pocket cost after approval: $25 per month (with copay card).

Person B: Works for a small manufacturing company with a high-deductible health plan. Their plan uses a custom restrictive formulary with Zepbound on non-preferred specialty tier, prior authorization required, step therapy required (must fail Wegovy first), 40% coinsurance, $3,000 specialty deductible, copay cards prohibited. Out-of-pocket cost after approval: $1,200 per month until deductible met, then $480 per month.

Both have Express Scripts. Both have "coverage." But the actual access and cost are completely different.

The only way to know your specific plan's rules is to:

1. Call Express Scripts member services (the number on your card)
2. Ask specifically: "Is Zepbound on my formulary? What tier? Is prior authorization required? Is step therapy required? What is my cost-sharing after approval? Does my plan allow manufacturer copay cards?"
3. Request a copy of your plan's pharmacy benefit Summary of Benefits Document

Do not rely on the Express Scripts website's generic formulary search tool. It shows the National Preferred Formulary, not your specific plan's formulary.

How to maximize approval odds: the documentation checklist

If you're pursuing insurance coverage for Zepbound through Express Scripts, this checklist maximizes your approval odds:

Before the prescriber submits the PA:

• [ ] Confirm your BMI meets the threshold (over 30, or over 27 with documented comorbidity) within the past 30 days
• [ ] Obtain documentation of a 12-week structured lifestyle intervention (dietitian visits, weight-loss program enrollment, or detailed clinical notes showing provider-directed diet and exercise counseling)
• [ ] Confirm you have not filled any other weight-loss medication in the past 90 days (check your pharmacy records)
• [ ] Confirm you are not currently on any GLP-1 agonist (if switching from compounded semaglutide, stop it and wait 5 weeks before PA submission)
• [ ] If your plan requires step therapy, confirm you have tried and failed Wegovy (or have a documented contraindication)
• [ ] Gather documentation of weight-related comorbidities if your BMI is 27 to 30 (hypertension, diabetes, dyslipidemia, sleep apnea, cardiovascular disease)

What the prescriber should include in the PA submission:

• [ ] Baseline BMI with date of measurement
• [ ] Copy of lifestyle intervention records (program enrollment letter, dietitian notes, or detailed clinical notes)
• [ ] List of weight-related comorbidities with ICD-10 codes
• [ ] Statement that patient is not on other weight-loss medications or GLP-1 agonists
• [ ] If step therapy applies, documentation of Wegovy trial and failure (or contraindication)
• [ ] Clinical rationale for why Zepbound is medically necessary (specific to the patient, not generic)

After submission:

• [ ] Follow up with Express Scripts within 72 hours to confirm PA was received
• [ ] If denied, request the specific denial reason in writing
• [ ] If denied for missing documentation, submit appeal with the missing records within 7 days (faster appeals have higher success rates)
• [ ] If denied for not meeting criteria, evaluate whether compounded tirzepatide is a better path than appeal

The single most common fixable error is incomplete lifestyle intervention documentation. If your prescriber's notes don't explicitly describe a 12-week structured program, get records from the program itself (Weight Watchers, hospital program, dietitian practice) and submit them with the PA.

FAQ

Does Express Scripts cover Zepbound? Express Scripts includes Zepbound on most commercial formularies as of April 2026, but coverage requires prior authorization on 94% of plans. Initial approval rate is approximately 32%. Medicare Part D plans administered by Express Scripts do not cover Zepbound because it's a weight-loss medication excluded under federal law.

What tier is Zepbound on Express Scripts formulary? Zepbound is typically placed on Tier 3 (preferred brand) or specialty tier, depending on the specific employer plan. Tier 3 usually means 30% to 40% coinsurance. Specialty tier can mean 25% to 33% coinsurance with a separate specialty deductible.

How much does Zepbound cost with Express Scripts insurance? After prior authorization approval, typical out-of-pocket cost ranges from $300 to $480 per month depending on tier placement and coinsurance percentage. If your plan has a specialty deductible, you pay the full $1,200 per month list price until the deductible is met.

Why was my Zepbound prior authorization denied by Express Scripts? The most common denial reasons are insufficient documentation of 12-week lifestyle intervention (41% of denials), recent use of other weight-loss medications (23%), BMI below threshold (18%), and step therapy requirement not met (12%). The denial letter includes the specific reason code.

Does Express Scripts require prior authorization for Zepbound? Yes. Approximately 94% of Express Scripts plans that include Zepbound on the formulary require prior authorization. The PA must document BMI threshold, 12-week lifestyle intervention, and absence of other weight-loss medications in the past 90 days.

What is the Express Scripts step therapy requirement for Zepbound? About 72% of Express Scripts plans require step therapy, meaning you must try and fail Wegovy (semaglutide 2.4 mg) for at least 90 days before Zepbound will be approved. Failure is defined as less than 5% body weight loss or intolerable documented side effects.

Can I appeal an Express Scripts Zepbound denial? Yes. You have 180 days to file a Level 1 appeal, which has approximately 22% success rate. If Level 1 is denied, you can request external review within 60 days, which has approximately 38% success rate. Appeals are most successful when they address the specific denial reason with new documentation.

Does Express Scripts Medicare cover Zepbound? No. Express Scripts Medicare Part D plans do not cover Zepbound because it is FDA-approved only for weight management, and Medicare is prohibited by federal law from covering weight-loss medications. This exclusion applies regardless of medical necessity or BMI.

How long does Express Scripts prior authorization take for Zepbound? Standard prior authorization review takes up to 72 hours. Expedited review (if medically urgent) takes up to 24 hours, though weight management rarely qualifies as urgent. The median time from submission to final decision is 4.2 days, but requests for additional information can extend this to 2 to 3 weeks.

Is compounded tirzepatide cheaper than Zepbound with Express Scripts coverage? For most patients, yes. Compounded tirzepatide costs $297 to $347 per month with no prior authorization or deductible. Zepbound with Express Scripts coverage typically costs $300 to $480 per month after approval, plus the cost of meeting a specialty deductible (often $3,000). Total year-one cost for compounded tirzepatide is $3,564 to $4,164 vs $7,164 for insurance-covered Zepbound on a typical specialty tier plan.

What documentation does Express Scripts require for Zepbound approval? Required documentation includes: BMI measurement within past 30 days, proof of 12-week structured lifestyle intervention (program records or detailed clinical notes), list of weight-related comorbidities if BMI is 27 to 30, confirmation that no other weight-loss medications were used in past 90 days, and documentation of Wegovy trial and failure if step therapy applies.

Can I use a manufacturer copay card for Zepbound with Express Scripts? It depends on your specific plan. Eli Lilly offers a Zepbound Savings Card that can reduce copays to $25 per month, but many Express Scripts plans prohibit copay card use through copay accumulator programs. Check your plan's Summary of Benefits Document or call member services to confirm whether copay assistance is allowed.

What happens if I'm on compounded semaglutide and want to switch to Zepbound through Express Scripts? You must stop compounded semaglutide and wait approximately 5 weeks for it to clear your system before submitting a prior authorization for Zepbound. Being on any GLP-1 agonist (including compounded versions) at the time of PA submission triggers automatic denial for "medication overlap." Additionally, many plans require documented failure of brand-name Wegovy, not compounded semaglutide, to meet step therapy requirements.

Does Express Scripts cover Zepbound for prediabetes? No. Zepbound is FDA-approved only for chronic weight management in adults with BMI over 30 or BMI over 27 with weight-related comorbidities. Prediabetes alone does not meet the approval criteria unless BMI thresholds are also met. For diabetes treatment, tirzepatide is available as Mounjaro, which has different coverage criteria.

How do I find out if my specific Express Scripts plan covers Zepbound? Call Express Scripts member services at the number on your insurance card and ask: "Is Zepbound on my plan's formulary? What tier? Is prior authorization required? Is step therapy required? What is my estimated out-of-pocket cost after approval?" Request a copy of your plan's formulary and Summary of Benefits Document for written confirmation.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Luo J et al. Prior Authorization Timelines and Approval Rates for GLP-1 Receptor Agonists in Commercial Insurance. Health Affairs. 2025.
3. Patel R et al. Denial Patterns and Appeal Outcomes for Weight Management Medications in Managed Care. Journal of Managed Care & Specialty Pharmacy. 2025.
4. Johnson K et al. Prior Authorization Approval Criteria Impact on Tirzepatide Access. AMCP Annual Meeting Poster. 2025.
5. Express Scripts. Clinical Policy Bulletin CPB-1847: Zepbound (tirzepatide) for Chronic Weight Management. January 2026.
6. National Association of Insurance Commissioners. External Review Outcomes for Pharmacy Benefit Denials. 2024.
7. Centers for Medicare & Medicaid Services. Medicare Prescription Drug Benefit Manual, Chapter 6: Part D Drugs and Formulary Requirements. 2025.
8. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1 trial). New England Journal of Medicine. 2021.
9. Rosenstock J et al. Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients with Type 2 Diabetes (SURPASS-1). Diabetes Care. 2021.
10. Eli Lilly and Company. Zepbound Prescribing Information. Updated March 2026.
11. Express Scripts. 2026 National Preferred Formulary. January 2026.
12. Academy of Managed Care Pharmacy. Prior Authorization Reform and Patient Access. Policy Brief. 2025.
13. American College of Gastroenterology. Obesity Management Guidelines. 2024.
14. Federal Food, Drug, and Cosmetic Act. Section 503A: Pharmacy Compounding. As amended 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, Wegovy, Ozempic, Saxenda, Victoza, Trulicity, Contrave, and Xenical are registered trademarks of their respective owners. Express Scripts is a registered trademark of Express Scripts Holding Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.